Drug intelligence / Profile preview

flovagatran

Development stage: Discontinued
Lead developer: Trigen Holdings
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

Flovagatran is a potent, reversible, low-molecular-weight synthetic direct thrombin inhibitor developed for the prevention and treatment of thrombosis. It belongs to the class of dipeptides and acts by selectively inhibiting thrombin (factor IIa), thereby preventing the conversion of fibrinogen to fibrin in the final step of the coagulation cascade. Flovagatran demonstrated promising pharmacokinetic properties and biological activity in preclinical studies but its clinical development was discontinued after Phase II trials for thrombosis[1][3][4][6][7].

Other names: flovagatran [INN]871576-03-3UNII-2WA50NUH6HUNII2WA50NUH6HUNII 2WA50NUH6H

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on flovagatran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flovagatran.

Explore the full profile